Cercar
29/06/2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study
Saumoy, M, Sanchez-Quesada, JL, Assoumou, L, Gatell, JM, Gonzalez-Cordon, A, Guaraldi, G, Domingo, P, Giacomelli, A, Connault, J, Katlama, C, Masia, M, Ordonez-Llanos, J, Pozniak, A, Martinez, E, Podzamczer, D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(7)DOI:10.1093/jac/dkac117. PMID:35411401. IF:5.200(Q1/3D).
27/06/2022
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E, Lynton-Pons, E, Domingo, P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.904686. PMID:35833134. IF:7.300(Q1/3D).
01/05/2022
Pulmonary Infections in People Living with HIV
Franquet, T, Domingo, P. Pulmonary Infections in People Living with HIV. RADIOLOGIC CLINICS OF NORTH AMERICA. 2022; 60(3)DOI:10.1016/j.rcl.2022.01.008. PMID:35534134. IF:1.900(Q3/8D).
01/03/2022
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Podzamczer, D, Mican, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, JM, Ribera, E, Vivancos, MJ, Morano, L, Masia, M, Gomez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, A, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macias, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernandez, G, Martinez, E, Moreno, S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3)DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4.200(Q2/4D).